Neuropathic pain and nerve damage induced by chemotherapy agents such as oxaliplatin and cisplatin are dose-limiting side effects of cancer treatment. In order to develop next-generation chemotherapeutic agents with improved side effect profiles, better characterized animal models are required to test the novel agents.
Charles River scientists recently characterized the previously described the oxaliplatin mouse model’s response to cool allodynia, or pain in response to cooling, using two behavioral tests—the tail immersion/flick test and the acetone cooling test. Cool allodynia occurred during and after oxaliplatin infusion, and is thought to arise from a direct effect of oxaliplatin on peripheral sensory neurons. Review the key findings and select data below, or click here to download the full poster.
Exposure to oxaliplatin led to persistent cool allodynia in the acetone test, which is a reliable method to test oxaliplatin-induced peripheral neuropathy.
Treatment with nerve pain medications, pregabalin and duloxetine, alleviated the allodynia response.
There was significant variation within each group (control and treated) in the tail immersion/flick test, suggesting that the tail immersion/flick test is not a reliable method to measure cool allodynia.